EQT X, through its indirectly owned subsidiary Oak BidCo S.à r.l., has secured an ownership of 72.5% of the votes in OEM International Aktiebolag (publ) and has announced a public cash offer to all shareholders. The shares of OEM International are admitted to trading on Nasdaq Stockholm, Mid Cap. The total value of the offer is approximately SEK 15.2 billion.

OEM International is one of Europe's leading technology trading companies with 34 operating units in 15 countries. The group operates in the trade of components and systems from leading suppliers in selected markets in Europe. A well-structured local market organisation and efficient logistics make OEM a better alternative to the supplier’s own sales organisations.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Joel Magnusson, Maximilian Bengtsson and Lovisa Jonassen (Capital Markets and Public M&A), Christina Kokko and Eléonore Friberg (M&A), Sebastian Örndahl, Noelia Martinez, Julia Rydin and Martin Hammarskiöld (Regulatory), Josefine Lanker (Banking and Finance), Christoffer Nordin and Elis Allmark (Commercial Agreements), Niclas Winnberg (Real Estate), Ebba Svenburg (Employment), Arvid Axelryd (Intellectual Property), Eva Fredriksson (IT), Hayaat Ibrahim (Compliance), Nicklas Thorgerzon (GDPR) and Julia Ulander Kull (Transaction Support Coordinator).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026